Where Does Johnson & Johnson Stock Rank Among Competitors?
Johnson & Johnson (JNJ) stock has soared over the past year, but how does it truly measure up against peers like Eli Lilly (LLY) and AbbVie (ABBV) rapidly scaling in innovative pharma and med-tech? Closer inspection reveals JNJ’s robust 26.2% operating margin and steady 5.1% LTM revenue growth. While its 22.9 PE offers moderate valuation support, growth trails some rivals, suggesting a balanced outlook amid competitive pressures and ongoing litigation.
- JNJ’s 26.2% operating margin signals strong efficiency and pricing power in its diverse healthcare segments, though below LLY’s 44.4% driven by highly profitable patented drugs.
- JNJ’s 5.1% revenue growth reflects stable demand, outpacing PFE and MRK due to patent challenges, but lagging LLY’s robust drug launches and ABBV/MDT’s specialized franchises.
- JNJ’s 60.6% gain, outperforming peers, reflects strong investor confidence in its diversified model and strategic moves, driving its 22.9 PE ratio.
Here’s how Johnson & Johnson stacks up across size, valuation, and profitability versus key peers.
| JNJ | PFE | MRK | LLY | ABBV | MDT | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 574.7 | 153.8 | 293.5 | 937.0 | 394.9 | 130.3 |
| Revenue ($ Bil) | 92.1 | 62.8 | 64.2 | 59.4 | 59.6 | 34.8 |
| PE Ratio | 22.9 | 15.6 | 15.4 | 50.9 | 165.4 | 27.4 |
| LTM Revenue Growth | 5.1% | 3.9% | 1.7% | 45.4% | 7.4% | 5.3% |
| LTM Operating Margin | 26.2% | 24.6% | 34.9% | 44.4% | 24.1% | 19.3% |
| LTM FCF Margin | 20.3% | 16.5% | 20.3% | 10.8% | 33.0% | 15.0% |
| 12M Market Return | 60.6% | 12.7% | 39.9% | 19.8% | 21.1% | 16.5% |
For more details on Johnson & Johnson, read Buy or Sell JNJ Stock. Below we compare JNJ’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| JNJ | 5.1% | – | 4.3% | 6.5% | 1.6% |
| PFE | 3.9% | – | 6.8% | -41.1% | 24.5% |
| MRK | 1.7% | – | 6.7% | 1.4% | 21.7% |
| LLY | 45.4% | – | 32.0% | 19.6% | 0.8% |
| ABBV | 7.4% | – | 3.7% | -6.4% | 3.3% |
| MDT | 5.3% | 3.6% | 3.6% | -1.4% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| JNJ | 26.2% | – | 24.9% | 27.5% | 26.3% |
| PFE | 24.6% | – | 23.3% | 7.1% | 36.7% |
| MRK | 34.9% | – | 31.5% | 4.9% | 30.8% |
| LLY | 44.4% | – | 37.8% | 30.3% | 29.0% |
| ABBV | 24.1% | – | 21.1% | 24.9% | 32.4% |
| MDT | 19.3% | 19.5% | 17.1% | 18.7% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| JNJ | 22.9 | – | 35.4 | 10.4 | 22.9 |
| PFE | 15.6 | – | 17.6 | 70.7 | 5.1 |
| MRK | 15.4 | – | 15.6 | 691.5 | 19.0 |
| LLY | 50.9 | – | 91.4 | 132.6 | 84.2 |
| ABBV | 165.4 | – | 94.5 | 64.6 | 23.2 |
| MDT | 27.4 | 26.5 | 28.9 | 29.2 |
Still not sure about JNJ stock? Consider portfolio approach.
Smart Wealth Management Means Diversifying Beyond Equities
Don’t let short-term market noise derail your long-term goals. A professional wealth framework helps you stay disciplined, turning volatility into opportunity.
Are you positioned to outperform over the next 1-3 years? We analyzed if adding allocations like 10% commodities and 10% gold to a standard stock-bond portfolio boosts returns. The results are clear: real assets matter. Our wealth management partner builds these robust portfolios to capture growth, while leveraging the Trefis High Quality Portfolio for superior stock selection.